Published online June 1, 2005
PEDIATRICS Vol. 115 No. 6 June 2005, pp. 1613-1622 (doi:10.1542/peds.2004-1004)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lipshultz, S. E.
Right arrow Articles by Colan, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lipshultz, S. E.
Right arrow Articles by Colan, S. D.
Related Collections
Right arrow Endocrinology

Cardiac Changes Associated With Growth Hormone Therapy Among Children Treated With Anthracyclines

Steven E. Lipshultz, MD*, Sarah A. Vlach, MD{ddagger}, Stuart R. Lipsitz, DSc§, Stephen E. Sallan, MD||,¶,#, Marcy L. Schwartz, MD{ddagger},¶ and Steven D. Colan, MD{ddagger},¶

* Department of Pediatrics, Miller School of Medicine at the University of Miami, Holtz Children's Hospital of the University of Miami-Jackson Memorial Medical Center, and the Sylvester Comprehensive Cancer Center, Miami, Florida
{ddagger} Department of Cardiology and
|| Division of Hematology-Oncology, Children's Hospital, Boston, Massachusetts
§ Department of Biometry and Epidemiology, Medical University of South Carolina, Charleston, South Carolina
Department of Pediatrics, Harvard Medical School, Boston, Massachusetts
# Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Objective. The objective was to assess the cardiac effects of growth hormone (GH) therapy. Anthracycline-treated childhood cancer survivors frequently have reduced left ventricular (LV) wall thickness and contractility, and GH therapy may affect these factors.

Methods. We examined serial cardiac findings for 34 anthracycline-treated childhood cancer survivors with several years of GH therapy and baseline cardiac z scores similar to those of a comparison group (86 similar cancer survivors without GH therapy).

Results. LV contractility was decreased among GH-treated patients before, during, and after GH therapy (–1.08 SD below the age-adjusted population mean before therapy and –1.88 SD 4 years after therapy ceased, with each value depressed below normal). Contractility was higher in the control group than in the GH-treated group, with this difference being nearly significant. The GH-treated children had thinner LV walls before GH therapy (–1.38 SD). Wall thickness increased during GH therapy (from –1.38 SD to –1.09 SD after 3 years of GH therapy), but the effect was lost shortly after GH therapy ended and thickness diminished over time (–1.50 SD at 1 year after therapy and –1.96 SD at 4 years). During GH therapy, the wall thickness for the GH-treated group was greater than that for the control group; however, by 4 years after therapy, there was no difference between the GH-treated group and the control group.

Conclusions. GH therapy among anthracycline-treated survivors of childhood cancer increased LV wall thickness, but the effect was lost after therapy was discontinued. The therapy did not affect the progressive LV dysfunction.

Key Words: growth hormone • anthracyclines • cardiac changes • cardiomyopathy • pediatric cancer • congestive heart failure

Abbreviations: LV, left ventricular • GH, growth hormone

Accepted Oct 6, 2004.




This article has been cited by other articles:


Home page
 HeartHome page
S. E Lipshultz, J. A Alvarez, and R. E Scully
Anthracycline associated cardiotoxicity in survivors of childhood cancer
Heart, April 1, 2008; 94(4): 525 - 533.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Follin, U. Thilen, B. Ahren, and E. M. Erfurth
Improvement in Cardiac Systolic Function and Reduced Prevalence of Metabolic Syndrome after Two Years of Growth Hormone (GH) Treatment in GH-Deficient Adult Survivors of Childhood-Onset Acute Lymphoblastic Leukemia
J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1872 - 1875.
[Abstract] [Full Text] [PDF]